Analysed VERASTEM INC (VSTM:NASDAQ) News Sources
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
23-06-2026
yahoo.com
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
23-06-2026
yahoo.com
Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?
25-06-2026
yahoo.com
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-07-2026
yahoo.com
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
22-07-2026
yahoo.com
What is the current price of VERASTEM INC (VSTM:NASDAQ)?
The current price of VERASTEM INC (VSTM:NASDAQ) is $6.
VERASTEM INC (VSTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of VERASTEM INC (VSTM:NASDAQ) since the previous trading day is $-0.08.
VERASTEM INC (VSTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of VERASTEM INC (VSTM:NASDAQ) since the previous trading day is -1.3158%.
What is the most recent average sentiment score for VERASTEM INC (VSTM:NASDAQ)?
The most recent average sentiment score for VERASTEM INC (VSTM:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for VERASTEM INC (VSTM:NASDAQ)?
The most recent sentiment for VERASTEM INC (VSTM:NASDAQ) is .
SEC-8K** Filing Available For VERASTEM INC (VSTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.